Renal involvement is frequent in COVID-19 (4-37%). This study evaluated the incidence and risk factors of acute kidney injury (AKI) in hospitalized patients with COVID-19. Methodology: This study represents a prospective cohort in a public and tertiary university hospital in São Paulo, Brazil, during the first 90 days of the COVID-19 pandemic, with patients followed up until the clinical outcome (discharge or death). Results: There were 101 patients hospitalized with COVID-19, of which 51.9% were admitted to the intensive care unit (ICU). The overall AKI incidence was 50%; 36.8% had hematuria or proteinuria (66.6% of those with AKI), 10.2% had rhabdomyolysis, and mortality was 36.6%. Of the ICU patients, AKI occurred in 77.3% and the mortality was 65.4%. The mean time for the AKI diagnosis was 6 ± 2 days, and Kidney Disease Improving Global Outcomes (KDIGO) stage 3 AKI was the most frequent (58.9%). Acute renal replacement therapy was indicated in 61.5% of patients. The factors associated with AKI were obesity [odds ratio (OR) 1.98, 95% confidence interval (CI) 1.04-2.76, p < 0.05] and the APACHE II score (OR 1.97, 95% CI 1.08-2.64, p < 0.05). Mortality was higher in the elderly (OR 1.03, 95% CI 1.01-1.66, p < 0.05), in those with the highest APACHE II score (OR 1.08, 95% CI 1.02-1.98, p < 0.05), and in the presence of KDIGO stage 3 AKI (OR 1.11, 95% CI 1.05-2.57, p < 0.05). Conclusion: AKI associated with severe COVID-19 in this Brazilian cohort was more frequent than Chinese, European, and North American data, and the risk factors associated with its development were obesity and higher APACHE II scores. Mortality was high, mainly in elderly patients, in those with a more severe disease manifestation, and in those who developed KDIGO stage 3 AKI.
Renal involvement is frequent in COVID-19 (4-37%). This study evaluated the incidence and risk factors of acute kidney injury (AKI) in hospitalized patients with COVID-19. Methodology: This study represents a prospective cohort in a public and tertiary university hospital in São Paulo, Brazil, during the first 90 days of the COVID-19 pandemic, with patients followed up until the clinical outcome (discharge or death). Results: There were 101 patients hospitalized with COVID-19, of which 51.9% were admitted to the intensive care unit (ICU). The overall AKI incidence was 50%; 36.8% had hematuria or proteinuria (66.6% of those with AKI), 10.2% had rhabdomyolysis, and mortality was 36.6%. Of the ICU patients, AKI occurred in 77.3% and the mortality was 65.4%. The mean time for the AKI diagnosis was 6 ± 2 days, and Kidney Disease Improving Global Outcomes (KDIGO) stage 3 AKI was the most frequent (58.9%). Acute renal replacement therapy was indicated in 61.5% of patients. The factors associated with AKI were obesity [odds ratio (OR) 1.98, 95% confidence interval (CI) 1.04-2.76, p < 0.05] and the APACHE II score (OR 1.97, 95% CI 1.08-2.64, p < 0.05). Mortality was higher in the elderly (OR 1.03, 95% CI 1.01-1.66, p < 0.05), in those with the highest APACHE II score (OR 1.08, 95% CI 1.02-1.98, p < 0.05), and in the presence of KDIGO stage 3 AKI (OR 1.11, 95% CI 1.05-2.57, p < 0.05). Conclusion: AKI associated with severe COVID-19 in this Brazilian cohort was more frequent than Chinese, European, and North American data, and the risk factors associated with its development were obesity and higher APACHE II scores. Mortality was high, mainly in elderly patients, in those with a more severe disease manifestation, and in those who developed KDIGO stage 3 AKI.
Authors: Rinaldo Bellomo; Claudio Ronco; Ravindra L Mehta; Pierre Asfar; Julie Boisramé-Helms; Michael Darmon; Jean-Luc Diehl; Jacques Duranteau; Eric A J Hoste; Joannes-Boyau Olivier; Matthieu Legrand; Nicolas Lerolle; Manu L N G Malbrain; Johan Mårtensson; Heleen M Oudemans-van Straaten; Jean-Jacques Parienti; Didier Payen; Sophie Perinel; Esther Peters; Peter Pickkers; Eric Rondeau; Miet Schetz; Christophe Vinsonneau; Julia Wendon; Ling Zhang; Pierre-François Laterre Journal: Ann Intensive Care Date: 2017-05-04 Impact factor: 6.925
Authors: Alexander Zarbock; John A Kellum; Christoph Schmidt; Hugo Van Aken; Carola Wempe; Hermann Pavenstädt; Andreea Boanta; Joachim Gerß; Melanie Meersch Journal: JAMA Date: 2016 May 24-31 Impact factor: 56.272
Authors: Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin Journal: Crit Care Date: 2007 Impact factor: 9.097
Authors: Isaac Ghinai; Tristan D McPherson; Jennifer C Hunter; Hannah L Kirking; Demian Christiansen; Kiran Joshi; Rachel Rubin; Shirley Morales-Estrada; Stephanie R Black; Massimo Pacilli; Marielle J Fricchione; Rashmi K Chugh; Kelly A Walblay; N Seema Ahmed; William C Stoecker; Nausheen F Hasan; Deborah P Burdsall; Heather E Reese; Megan Wallace; Chen Wang; Darcie Moeller; Jacqueline Korpics; Shannon A Novosad; Isaac Benowitz; Max W Jacobs; Vishal S Dasari; Megan T Patel; Judy Kauerauf; E Matt Charles; Ngozi O Ezike; Victoria Chu; Claire M Midgley; Melissa A Rolfes; Susan I Gerber; Xiaoyan Lu; Stephen Lindstrom; Jennifer R Verani; Jennifer E Layden Journal: Lancet Date: 2020-03-13 Impact factor: 79.321
Authors: A Cau; M P Cheng; Terry Lee; A Levin; T C Lee; D C Vinh; F Lamontagne; J Singer; K R Walley; S Murthy; D Patrick; O Rewa; B Winston; J Marshall; J Boyd; J A Russell Journal: Can J Kidney Health Dis Date: 2021-10-30
Authors: Tyler Pitre; Angela Hong Tian Dong; Aaron Jones; Jessica Kapralik; Sonya Cui; Jasmine Mah; Wryan Helmeczi; Johnny Su; Vivek Patel; Zaka Zia; Michael Mallender; Xinxin Tang; Cooper Webb; Nivedh Patro; Mats Junek; MyLinh Duong; Terence Ho; Marla K Beauchamp; Andrew P Costa; Rebecca Kruisselbrink; Jennifer L Y Tsang; Michael Walsh Journal: Can J Kidney Health Dis Date: 2021-07-11